{
  "docId": "019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "docSlug": "78e7004510e3b27003e9c94a6172e682",
  "documentTitle": "Chimerix | Investor Presentation Deck | 38 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 38,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Includes footnote references for data sources and royalty obligations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-80bf-72b8-b7b1-d0f771f9e60f/31",
  "deckHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "deckJsonHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f.json",
  "deckAnchorHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.08,
        "y": 0.5
      },
      "kind": "image",
      "text": "1 out of 20 icon array",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99d9ab03-c415-45d8-8b5c-0ea7c6f2a608",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.62
      },
      "kind": "list",
      "text": "Chimerix retains global operational rights to ONC206",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "050866ef-5ead-4cb4-9a36-61917d20d9e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.03,
        "y": 0.41
      },
      "kind": "list",
      "text": "Existing therapies rarely offer durable effect: 3-year survival from diagnosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a8589ba-e2db-458e-a074-b0a2fcfbc2d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "GBM is a rapidly progressive disease with low survival rates, few drug approvals last 25 years: Temozolomide (TMZ) approved 1999, Bevacizumab approved 2009",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa7cc3fd-0769-48a2-8abd-e7bc8aa147d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.03,
        "y": 0.68
      },
      "kind": "list",
      "text": "Worldwide market opportunity exceeds $2Bn: TMZ revenue peaked at ~$1.4B in 2009 (>$2.5B inflation adjusted); New GBM therapy >$2Bn",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e653d897-f71d-4348-ab75-3572bca045f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.1,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1 wjso.biomedcentral.com/articles/10.1186/1477-7819-10-220 2 Royalties and milestones are owed to legacy Oncoceutics shareholders by virtue of the 2021 merger agreement",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d15e7343-0d9f-4ce0-be42-ab1ed82911a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.84,
        "x": 0.08,
        "y": 0.05
      },
      "kind": "title",
      "text": "~30,000 new cases of GBM annually in the top 7 markets; >$2Bn market opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f64d9e36-9048-43fe-acbe-08898b0d2889",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "604f26e4-a1e2-44fe-afe6-3cf62decd531",
      "evidence": "top 7 markets",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 31,
      "from": 31,
      "beatId": "3c3f4af4-489f-4bb2-848d-69bcfa5c0a10",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document provides market sizing information, highlighting the potential for ONC201.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}